Professional Documents
Culture Documents
CPG Diabetes in Pregnancy
CPG Diabetes in Pregnancy
Published by:
Malaysia Health Technology Assessment Section (MaHTAS)
Medical Development Division, Ministry of Health Malaysia
Level 4, Block E1, Precinct 1
Federal Government Administrative Centre
62590, Putrajaya, Malaysia
Copyright
The copyright owner of this publication is MaHTAS. Content may be
reproduced in any number of copies and in any format or medium
provided that a copyright acknowledgement to MaHTAS is included and
the content is not changed, not sold, nor used to promote or endorse
any product or service, and not used in an inappropriate or misleading
context.
ISBN: 978-967-2173-15-1
STATEMENT OF INTENT
TABLE OF CONTENTS
TABLE OF CONTENTS
LEVELS OF EVIDENCE
Level Study design
FORMULATION OF RECOMMENDATION
i
Management of Diabetes in Pregnancy
KEY RECOMMENDATIONS
Screening
Preconception Care
ii
Management of Diabetes in Pregnancy
iii
Management of Diabetes in Pregnancy
iv
Management of Diabetes in Pregnancy
GUIDELINES DEVELOPMENT
The members of the Development Group (DG) for these CPG were
from the Ministry of Health (MoH) and Ministry of Higher Education
(MoHE). There was active involvement of a multidisciplinary Review
Committee (RC) during the process of the CPG development.
v
Management of Diabetes in Pregnancy
The literatures used in these guidelines were graded using the US/
Canadian Preventive Services Task Force Level of Evidence (2001)
while the grading of recommendation was done using the principles of
GRADE (refer to the preceding page). The writing of the CPG follows
strictly the requirement of AGREE II.
vi
Management of Diabetes in Pregnancy
OBJECTIVES
CLINICAL QUESTIONS
Refer to Appendix 2
TARGET POPULATION
Inclusion Criteria
i. Women with diabetes planning for pregnancy
ii. Pregnant women at risk of diabetes
iii. Pregnant women with pre-existing diabetes and gestational diabetes
mellitus
Exclusion Criteria
Pregnant women with secondary causes of diabetes
TARGET GROUP/USER
HEALTHCARE SETTINGS
vii
Management of Diabetes in Pregnancy
DEVELOPMENT GROUP
Chairperson
Dr. Hoong Farn Weng Michael Assoc. Prof. Dr. Norasyikin Abdul Wahab
Consultant Obstetrician & Gynaecologist Lecturer & Consultant Endocrinologist
Hospital Wanita & Kanak-kanak Sabah Faculty of Medicine
Sabah Universiti Kebangsaan Malaysia
Kuala Lumpur
viii
Management of Diabetes in Pregnancy
REVIEW COMMITTEE
The draft CPG was reviewed by a panel of experts from both public
and public sectors. They were asked to comment primarily on the
comprehensiveness and accuracy of the interpretation of evidence
supporting the recommendations in the CPG.
Chairperson
Dr. Zanariah Hussein
Senior Consultant Endocrinologist &
National Advisor of Endocrinology Services
Hospital Putrajaya, Putrajaya
ix
Management of Diabetes in Pregnancy
x
Management of Diabetes in Pregnancy
SCREENING*
• Women at risk to develop GDM**: at booking/as early as possible
• Women age ≥25 with no other risk factors: at 24-28 weeks of gestation
OGTT results
Fasting plasma glucose (FPG): ≥5.1 mmol/L
OR
2-hours postprandial (2-HPP) ≥7.8 mmol/L
YES NO
YES
FPG ≥5.1 mmol/L OR 2-HPP ≥7.8 mmol/L
NO
Exclude GDM
xi
Management of Diabetes in Pregnancy
T2DM or
T1DM GDM on insulin/ GDM on diet alone
metformin
xii
Management of Diabetes in Pregnancy
CBG results
(Target: 4.0-7.0 mmol/L)
xiii
Management of Diabetes in Pregnancy
Management of Diabetes in Pregnancy
1. INTRODUCTION
The National Health Morbidity Survey 2015 showed that the prevalence
of diabetes was 17.5%. Generally, the prevalence of diabetes increases
with age.1, level III This is a concern especially in the reproductive age
group as this will adversely affect their fertility and pregnancy.
1
Management of Diabetes in Pregnancy
2
Management of Diabetes in Pregnancy
Recommendation 1
• Screening for gestational diabetes mellitus based on risk factors*
using 75 gram oral glucose tolerance test (OGTT) should be done at
booking.
If the test is negative, it should be repeated at 24-28 weeks of
gestation.
• For women at the age of 25 or more with no other risk factors, OGTT
should be done at 24-28 weeks of gestation.
• Overt diabetes in pregnancy should be managed as pre-existing
diabetes.
3
Management of Diabetes in Pregnancy
4
Management of Diabetes in Pregnancy
• In the local setting, the BMI criteria for overweight is 23.0-27.4 kg/m2
and obesity is ≥27.5 kg/m2.19 There is no recommendations on total
and rates of weight gain for local population. However, targeting
GWG to the lower range in Table 1 may be recommended to improve
pregnancy outcomes.
GWG is the major determinant of incremental energy needs during
pregnancy. Energy prescription should be individualised based on
pre-pregnancy BMI, weight gain, fetal growth pattern, physical activity,
food and blood glucose records.
• For women with normal pre-pregnancy BMI, energy prescriptions
(approximately ranges from 30-35 kcal/kg body weight depending on
activity level) should be given as per normal pregnancy based on the
Recommended Nutrient Intakes for Malaysia.4
• For obese women, a 30-33% of calorie restriction of their estimated
energy needs (approximately 25 kcal/kg body weight) can be
prescribed to reduce the rate of GWG without inducing maternal
ketosis and compromising fetal growth or birth weight. The GWG
must be closely monitored, and the additional energy needs during
pregnancy should be modified accordingly.20, level III
5
Management of Diabetes in Pregnancy
Recommendation 2
• Pregnant women at risk of gestational diabetes mellitus should
be offered medical nutrition therapy which includes monitoring of
gestational weight gain.
3.2 EXERCISE
Recommendation 3
• All pregnant women with uncomplicated pregnancies should
be encouraged to exercise especially those at risk of developing
gestational diabetes mellitus.
6
Management of Diabetes in Pregnancy
7
Management of Diabetes in Pregnancy
• Medication review
Women with T2DM who are planning a pregnancy should switch
from oral antidiabetic agent (OAD) to insulin for glycaemic control.
Patients who are already on metformin may continue treatment.6
Women with pre-existing diabetes who also have polycystic
ovarian syndrome may continue metformin for ovulation induction.
Prior to conception or upon detection of pregnancy, the following
medications should be discontinued: angiotensin-converting
enzyme inhibitors, angiotensin II receptor blockers and statins.6
4.2 CONTRACEPTION
The synthetic form of folate is folic acid (FA) which is often used in
supplements and fortified foods. The main function of folate is to act as
the co-enzyme in one-carbon transfer during the methylation cycle, an
essential process for the syntheses of nucleic acids, which form part
of deoxyribonucleic acid and neurotransmitters. Folate also plays an
8
Management of Diabetes in Pregnancy
Recommendation 4
• Preconception care of women with pre-existing diabetes which
involve a multidisciplinary team should be fully implemented in all
healthcare facilities.
• Supplement of 5 mg folic acid per day should be given to women
with diabetes who plan to become pregnant at least three months
prior to conception and continue until 12 weeks of gestation.
9
Management of Diabetes in Pregnancy
10
Management of Diabetes in Pregnancy
Recommendation 5
• Self-monitoring of blood glucose (SMBG) should be done in diabetes
in pregnancy. The blood glucose targets should be as the following:
fasting or preprandial: ≤5.3 mmol/L
1-hour postprandial: ≤7.8 mmol/L
2-hour postprandial: ≤6.7 mmol/L
• The frequency of SMBG in diabetes in pregnancy should be
individualised based on mode of treatment and glycaemic control.
• Pregnant women with pre-existing diabetes on multiple daily insulin
(MDI) injection regimen should perform SMBG at least three times
daily. It can be done at fasting, preprandial, postprandial or bedtime.
• Women with gestational diabetes mellitus (GDM) on MDI injection
regimen should perform SMBG two to three times daily, for two to
three days a week.
• Pregnant women with type 2 diabetes mellitus or GDM on diet
and exercise therapy, oral antidiabetic agents (OAD), single-dose
intermediate-acting or long-acting insulin should perform fasting and
postprandial SMBG at least once daily until blood glucose targets
are reached.
• Pregnant women who are on insulin or OAD should maintain their
capillary blood glucose level >4.0 mmol/L.
11
Management of Diabetes in Pregnancy
Evidence on the ideal amount of CHO for pregnant women with diabetes
to achieve good glycaemic control is limited, but a minimum of 175 g
CHO daily has been recommended.37, level III In a meta-analysis of RCTs
on GDM, lower CHO diets [40-45% of total energy intake (TEI)] showed
no significant difference in maternal and neonatal outcomes compared
with CHO intake of 55-60% TEI. This could be due to the small number
of studies included.38, level I
Both the amount and type of CHO influence glycaemic control. The type
of CHO is best described using glycaemic index (GI) concept. In a meta-
analysis on GDM, a low GI diet was more effective in reducing insulin
requirement (RR=0.767, 95% CI 0.597 to 0.986) compared with high
GI diet.38, level I In a recent Cochrane systematic review on GDM, low-
to-moderate GI showed no significant benefits in maternal outcomes
(severe hypertension or pre-eclampsia, eclampsia and rate of caesarean
section) and LGA compared with moderate-high GI diet. However, the
primary papers used in the review were of low quality.39, level I
12
Management of Diabetes in Pregnancy
Recommendation 6
• Pregnant women with diabetes should be given individualised
medical nutrition therapy which includes carbohydrate-controlled
meal plan and monitoring of gestational weight gain.
Metformin and glibenclamide are OAD that have been used in GDM.
Glibenclamide has limited human data and should only be used if
potential benefit outweighs the potential risk. Metformin is labelled as
FDA pregnancy category B while glibenclamide is in category C.
Category B: Animal studies have failed to demonstrate a risk to the fetus and there
are no adequate and well-controlled studies in pregnant women.
Category C: Animal studies have shown an adverse effect on the fetus and adequate
and well-controlled studies in humans were not available.
13
Management of Diabetes in Pregnancy
Recommendation 7
• In gestational diabetes mellitus, metformin should be offered when
blood glucose targets are not met by modification in diet and exercise
within 1-2 weeks.
It should be prescribed after consultation with specialists.
• Metformin should be continued in women who are already on the
treatment before pregnancy.
5.4 INSULIN
14
Management of Diabetes in Pregnancy
The use of human insulin, both short acting (regular) and intermediate
or long acting [Neutral Protamine Hagedorn (NPH)] have been
established in pregnancy. They are generally considered safe and
effective and labelled as FDA pregnancy category B. In the local setting,
human insulin is the preferred choice of insulin in view of its cost and
availability.
Insulin analogues mimic natural insulin physiology. There are rapid and
long acting (basal) insulin analogues which are currently used in pre-
existing diabetes during pregnancy and GDM. Insulin lispro and aspart
are labelled as FDA pregnancy category B. On the other hand, insulin
glulisine and glargine are labelled as FDA pregnancy category C (refer
footnote in page 13).
i. Insulin lispro
Insulin lispro significantly improves HbA1c and reduces total insulin
requirement in pre-existing diabetes in pregnancy compared with
regular insulin. Apart from that, it is associated with greater mean birth
weight and lower hyperbilirubinaemia. There is no significant difference
in other maternal and fetal outcomes.47, level II-2
i. Insulin detemir
There is no difference in HbA1c when comparing insulin detemir with
NPH in pregnant T1DM women although insulin detemir group has
significantly lower FPG at 24 and 36 weeks. Insulin requirement and
rate of hypoglycaemia are similar in both groups.48, level I There is no
significant difference in the incidence of composite pregnancy outcomes
which include fetal and perinatal mortality, and major malformations.
49, level I
15
Management of Diabetes in Pregnancy
16
Management of Diabetes in Pregnancy
Recommendation 8
• Insulin therapy can be initiated at outpatient setting in pregnant
women with diabetes.
• The preferred choice of insulin regime in diabetes in pregnancy is
multiple daily injections.
• Insulin analogues should be continued during pregnancy in women
with pre-existing diabetes who are already on the treatment and
have established good blood glucose control before pregnancy.
• Rapid-acting insulin analogue may be considered as an option,
particularly in patients with frequent hypoglycaemia or postprandial
hyperglycaemia using human insulin during pregnancy.
17
Management of Diabetes in Pregnancy
Recommendation 9
• Low dose aspirin (75-150 mg daily) should be given to prevent pre-
eclampsia in women with pre-existing diabetes from 12 weeks of
gestation until term.
• Vitamin C and E supplementation should not be given to prevent
pre-eclampsia in women with diabetes.
If renal assessment has not been done in the preceding three months
in women with pre-existing diabetes, arrange it during the first antenatal
visit. Referral to a nephrologist should be considered when:6
• serum creatinine is abnormal (120 µmol/L or more); estimated
glomerular filtration rate should not be used during pregnancy
• the urinary albumin: creatinine ratio (ACR) >30 mg/mmol
• total protein excretion exceeds 0.5 g/day
18
Management of Diabetes in Pregnancy
Recommendation 10
• In women with pre-existing diabetes,
retinal assessment should be performed at booking and repeated
at least once throughout the pregnancy
renal assessment should be performed at booking; those with pre-
existing renal disease should be managed in a combined clinic
Timing Parameters
19
Management of Diabetes in Pregnancy
Recommendation 11
• Pregnant women with pre-existing diabetes should be offered
ultrasound scan at:
11-14 weeks of gestation for dating and assessment of major
structural malformation
18-20 weeks of gestation for detailed structural anatomy scan (by
a trained specialist or sonographer)
• In pregnant women with pre-existing diabetes and gestational
diabetes mellitus, serial growth scan should be performed every
four weeks from 28 to 36 weeks of gestation.
20
Management of Diabetes in Pregnancy
Recommendation 12
• The following should be planned for pregnant women with pre-
existing diabetes:
without complications, delivery between 37+0 and 38+6 weeks
with maternal or fetal complications, delivery before 37+0 weeks
• The following should be planned for women with gestational
diabetes:
on diet alone with no complications, delivery before 40+0 weeks
on oral antidiabetic agents or insulin, delivery between 37+0 and
38+6 weeks
with maternal or fetal complications, deliver before 37+0 weeks
• Mode of delivery should be individualised, taking into consideration
the estimated fetal weight and obstetric factors.
• Women with diabetes who receive antenatal corticosteroids for
fetal lung maturation should have close monitoring of blood glucose
levels and insulin dose adjusted accordingly.
21
Management of Diabetes in Pregnancy
Current recommendations for intrapartum glycaemic control are:6; 33, level III
• monitor CBG every hour during labour and delivery, and ensure that
it is maintained at 4.0-7.0 mmol/L
• use IV dextrose and insulin for women with
T1DM from the onset of established labour
CBG >7.0 mmol/L
Recommendation 13
• In women with diabetes, capillary blood glucose should be
maintained at 4.0-7.0 mmol/L during labour and delivery.
• Monitoring of capillary blood glucose during labour and delivery in
women with diabetes should be done:
1- to 2-hourly in women on insulin treatment
4-hourly in women not on insulin treatment
22
Management of Diabetes in Pregnancy
23
Management of Diabetes in Pregnancy
7.3 BREASTFEEDING
Recommendation 14
• In women with history of gestational diabetes mellitus,
oral glucose tolerance test should be performed at six weeks
after delivery to detect diabetes and pre-diabetes; If the result is
negative, annual screening should be performed
metformin and intensive lifestyle intervention during postpartum
period should be considered to prevent diabetes
breastfeeding of at least three months or longer should be
encouraged to reduce the risk of diabetes
25
Management of Diabetes in Pregnancy
26
Management of Diabetes in Pregnancy
9.2 CORTICOSTEROIDS
9.3 FASTING
27
Management of Diabetes in Pregnancy
fetal complications. Thus, once or twice daily NPH insulin is safe and
tolerable for this group of pregnant women.91, level III
Recommendation 15
• Pregnant diabetes women should consult their healthcare providers
if they wish to observe fasting.
Recommendation 16
• Pregnant women with pre-existing diabetes and women with GDM
who have poor glycaemic control or fetal complications should be
referred to secondary or tertiary care.
28
Management of Diabetes in Pregnancy
29
Management of Diabetes in Pregnancy
Percentage
Number of women at risk of GDM
of women at
screened with 75-g OGTT
risk of GDM
at booking in a period
screened with = X 100%
75-g OGTT at Total number of women at risk of GDM
booking at booking in the same period
(target >85%)
Percentage
of women with
GDM who Number of women with GDM who had
had OGTT OGTT at six weeks postpartum
= X 100%
at six weeks
Total number of women with GDM
postpartum
(target >70%)
30
Management of Diabetes in Pregnancy
REFERENCES
1. Institute for Public Health. National Health and Morbidity Survey 2015. Volume.
II: Non-Communicable Diseases, Risk Factors & Other Health Problems; 2015.
2. Ravichandran J, Shamala DK. 3rd Report of National Obstetric Registry (2011-
2012). Malaysia: Ministry of Health. 2012. (Available at: http://www. acrm.org.
my/ nor/doc/reports/NOR_REPORT_2012.pdf)
3. Tieu J, McPhee AJ, Crowther CA, et al. Screening and subsequent management
for gestational diabetes for improving maternal and infant health. Cochrane
Database Syst Rev. 2014;(2):CD007222.
4. Malaysian Endocrine & Metabolic Society and Ministry of Health Malaysia.
Management of Type 2 Diabetes Mellitus (5th Edition). Kuala Lumpur: MEMS &
MOH; 2015.
5. Farrar D, Duley L, Medley N, et al. Different strategies for diagnosing gestational
diabetes to improve maternal and infant health. Cochrane Database Syst Rev.
2015; 1:CD007122.
6. National Collaborating Centre for Women’s and Children’s Health (UK). Diabetes
in pregnancy: management of diabetes and its complications from preconception
to the postnatal period. London: NICE; 2015.
7. American Diabetes Association. 2. Classification and diagnosis of diabetes.
Diabetes care. 2015;38(Supplement 1):S8-16.
8. International Association of Diabetes and Pregnancy Study Groups Consensus
Panel. International association of diabetes and pregnancy study groups
recommendations on the diagnosis and classification of hyperglycemia in
pregnancy. Diabetes care. 2010;33(3):676-682.
9. Lowe LP, Metzger BE, Dyer AR, et al. Hyperglycemia and Adverse Pregnancy
Outcome (HAPO) Study: associations of maternal A1C and glucose with
pregnancy outcomes. Diabetes Care. 2012;35(3):574-580.
10. van Leeuwen M, Opmeer BC, Yilmaz Y, et al. Accuracy of the random glucose
test as screening test for gestational diabetes mellitus: a systematic review. Eur
J Obstet Gynecol Reprod Biol. 2011;154(2):130-135.
11. Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine
society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(11):4227-
4249.
12. Ministry of Health. Screening, Diagnosis and Management of Gestational
Diabetes in New Zealand: A clinical practice guideline. Wellington: Ministry of
Health. 2014.
13. Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine
society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(11):4227-
4249.
14. “In pregnant women at risk for GDM, what is the effectiveness of MNT intervention
by an RDN to prevent the development of GDM”. Academy of Nutrition and Dietetics.
(Available at: https://www.andeal.org/topic.cfm?menu=5288&cat=5698).
15. Murphy A, Guilar A, Donat D. Nutrition education for women with newly
diagnosed gestational diabetes mellitus: small-group vs. individual counselling.
Can J Diabetes. 2004;28(2):00-0.
16. Song C, Li J, Leng J, et al. Lifestyle intervention can reduce the risk of
gestational diabetes: a meta-analysis of randomized controlled trials. Obes Rev.
2016;17(10):960-969.
17. Tieu J, Shepherd E, Middleton P, et al. Dietary advice interventions in pregnancy
for preventing gestational diabetes mellitus. Cochrane Database Syst Rev.
2017;1:CD006674.
18. Keely E, Barbour LA. Management of diabetes in pregnancy. Updated on 14
February 2014. (Available at: https://www.ncbi.nlm.nih.gov/books/NBK279010/)
19. Malaysian Endocrine & Metabolic Society and Ministry of Health Malaysia.
Management of Obesity. Kuala Lumpur: MEMS & MOH; 2004.
31
Management of Diabetes in Pregnancy
20. “In women with GDM, what is the effect of caloric consumption on fetal/neonatal
and maternal outcomes?”. Academy of Nutrition and Dietetics. (Available
at:https://www.andeal.org/topic.cfm?cat=5503&conclusion_statement_
id=252481).
21. Bruno R, Petrella E, Bertarini V, et al. Adherence to a lifestyle programme in
overweight/obese pregnant women and effect on gestational diabetes mellitus:
a randomized controlled trial. Matern Child Nutr. 2017;13(3).
22. Sanabria-Martínez G, García-Hermoso A, Poyatos-León R, et al. Effectiveness
of physical activity interventions on preventing gestational diabetes mellitus and
excessive maternal weight gain: a meta-analysis. BJOG. 2015;122(9):1167-
1174.
23. ACOG Committee on Obstetric Practice. Committee opinion# 650: Physical
activity and exercise during pregnancy and the postpartum period. The American
College of Obstetricians and Gynaecologists. Dec 2015. (Available at: https://
www.acog.org/-/media/Committee-Opinions/Committee-on-Obstetric-Practice/
co650.pdf?dmc=1).
24. Wahabi HA, Alzeidan RA, Bawazeer GA, et al. Preconception care for diabetic
women for improving maternal and fetal outcomes: a systematic review and
meta-analysis. BMC Pregnancy Childbirth. 2010;10:63.
25. Tieu J, Bain E, Middleton P, et al. Interconception care for women with a history
of gestational diabetes for improving maternal and infant outcomes. Cochrane
Database Syst Rev. 2013;(6):CD010211.
26. Kapoor N, Sankaran S, Hyer S, et al. Diabetes in pregnancy: a review of current
evidence. Curr Opin Obstet Gynecol. 2007;19(6):586-590.
27. Joslin Diabetes Center and Joslin Clinic Guideline for Detection and Management
of Diabetes in Pregnancy (Available at: http://www.joslin.org/docs/ Pregnancy-
Guidelines_11-13-2016_corrected_1-11-2017.pdf) Accessed on: 20/09/2016.
28. Holmes VA, Young IS, Patterson CC, et al.; Diabetes and Pre-eclampsia
Intervention Trial Study Group. Optimal glycemic control, pre-eclampsia, and
gestational hypertension in women with type 1 diabetes in the diabetes and pre-
eclampsia intervention trial. Diabetes Care. 2011;34(8):1683-1688.
29. World Health Organization. Standards for maternal and neonatal care. 2007.
(Available at: http://apps.who.int/iris/bitstream/10665/69735/1/a91272.pdf).
30. De-Regil LM, Peña-Rosas JP, Fernández-Gaxiola AC, et al. Effects and safety
of periconceptional oral folate supplementation for preventing birth defects.
Cochrane Database Syst Rev. 2015;(12):CD007950.
31. Correa A, Gilboa SM, Botto LD, Moore CA, et al; National Birth Defects
Prevention Study. Lack of periconceptional vitamins or supplements that contain
folic acid and diabetes mellitus-associated birth defects. Am J Obstet Gynecol.
2012;206(3):218.e1-13.
32. Allen VM, Armson BA; Genetics Committee; Maternal Fetal Medicine Committee.
Teratogenicity associated with pre-existing and gestational diabetes. J Obstet
Gynaecol Can. 2007;29(11):927-934
33. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee.
Canadian Diabetes Association 2013 Clinical Practice Guidelines for the
Prevention and Management of Diabetes in Canada. Can J Diabetes
2013;37(suppl 1):S1-S212. (update in 2016). (Available at: http://guidelines.
diabetes.ca/browse/chapter36).
34. Moy FM, Ray A, Buckley BS. Techniques of monitoring blood glucose during
pregnancy for women with pre-existing diabetes. Cochrane Database Syst Rev.
2014;(4):CD009613.
35. Hartling L, Dryden DM, Guthrie A, et al. Benefits and harms of treating gestational
diabetes mellitus: a systematic review and meta-analysis for the U.S. Preventive
Services Task Force and the National Institutes of Health Office of Medical
Applications of Research. Ann Intern Med. 2013;159(2):123-129.
32
Management of Diabetes in Pregnancy
33
Management of Diabetes in Pregnancy
34
Management of Diabetes in Pregnancy
35
Management of Diabetes in Pregnancy
86. O’Reilly SL, Dunbar JA, Versace V, et al.; MAGDA Study Group. Mothers after
Gestational Diabetes in Australia (MAGDA): A Randomised Controlled Trial of a
Postnatal Diabetes Prevention Program. PLoS Med. 2016;13(7):e1002092.
87. Farrar D, Tuffnell DJ, West J, et al. Continuous subcutaneous insulin infusion
versus multiple daily injections of insulin for pregnant women with diabetes.
Cochrane Database Syst Rev. 2016;(6):CD005542.
88. Kreiner A, Gil K, Lavin J. The effect of antenatal corticosteroids on maternal
serum glucose in women with diabetes. Open Journal of Obstetrics and
Gynecology 2. 2012;112-115.
89. Refuerzo JS, Garg A, Rech B, et al. Continuous glucose monitoring in diabetic
women following antenatal corticosteroid therapy: a pilot study. Am J Perinatol.
2012;29(5):335-338.
90. Ministry of Health Malaysia and Malaysian Endocrine & Metabolic Society.
Practical guide to diabetes management in Ramadan. Kuala Lumpur: MEMS &
MOH; 2015.
91. Nor Azlin MI, Adam R, Sufian SS, et al. Safety and tolerability of once or twice
daily neutral protamine hagedorn insulin in fasting pregnant women with diabetes
during Ramadan. J Obstet Gynaecol Res. 2011;37(2):132-137.
92. Ismail NA, Olaide Raji H, Abd Wahab N, et al. Glycemic Control among Pregnant
Diabetic Women on Insulin Who Fasted During Ramadan. Iran J Med Sci.
2011;36(4):254-259.
36
Management of Diabetes in Pregnancy
Appendix 1
Clinical Question: What are the effective and safe screening strategies
for diabetes in pregnancy?
1. DIABETES, GESTATIONAL/
2. (gestational adj1 diabetes mellitus).tw.
3. (diabetes adj1 (pregnancy-induced or pregnancy induced or
gestational)).tw.
4. PREGNANCY IN DIABETICS/
5. pregnancy in diabet*.tw.
6. DIABETES MELLITUS/
7. diabetes mellitus.tw.
8. DM.tw.
9. DIABETES MELLITUS, TYPE 1/
10. iddm.tw.
11. (diabetes mellitus adj1 (insulin-dependent or insulin dependent or
insulin-dependent 1 or insulin dependent 1 or type 1)).tw.
12. DIABETES MELLITUS, TYPE 2/
13. niddm.tw.
14. (diabetes mellitus adj1 (non-insulin-dependent or noninsulin-
dependent or noninsulin dependent or non insulin dependent or
type 2)).tw.
15. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14
16. PREGNANCY/
17. pregnanc*.tw.
18. 16 or 17
19. 15 and 18
20. 1 or 2 or 3 or 4 or 5 or 19
21. MASS SCREENING/
22. screen*.tw.
23. (mass adj1 screen*).tw.
24. 21 or 22 or 23
25. 20 and 24
26. limit 25 to (english language and humans and yr=”2006 -Current”)
37
Management of Diabetes in Pregnancy
Appendix 2
CLINICAL QUESTIONS
1. What are the effective and safe screening strategies for diabetes
in pregnancy?
2. What are the methods to diagnose GDM?
3. Are the following interventions effective and safe in pre-existing
diabetes? (preconception care and counselling, exercise,
contraception, glycaemic/metabolic control, supplementations)
4. Are the following antenatal management effective and safe in
non-diabetes pregnant women at risk of gestational diabetes?
(lifestyle modification, exercise, medical nutrition therapy [MNT])
5. Are the following antenatal management effective and safe in
pre-existing diabetes and gestational diabetes? (glycaemic/
metabolic control, timing and mode of delivery, pre-eclampsia
prophylaxis, MNT, fetal surveillance, screening for congenital
malformation)
6. Are oral antidiabetic agents effective and safe in pre-existing
diabetes and gestational diabetes?
7. Is insulin analogue effective and safe in pre-existing diabetes and
gestational diabetes?
8. Are the following intrapartum management (spontaneous vaginal
delivery/caesarean section) effective and safe in pre-existing
diabetes and gestational diabetes? (blood glucose target, insulin
regime)
9. Are the following postpartum management effective and safe
in pre-existing diabetes and gestational diabetes? (postpartum
glucose monitoring, modification of the treatment, breastfeeding,
contraception counselling)
10. What are the effective and safe management of specific conditions
in pregnancy? (use of corticosteroids, use of insulin pumps,
fasting)
11. What are the effective and safe management for infants of diabetic
mothers?
12. What are the indications for referral to secondary/tertiary care?
38
Management of Diabetes in Pregnancy
Appendix 3
Sources: 1. Tee ES, Mohd Ismail N, Mohd Nasir A, et al. Nutrient Composition
of Malaysian Foods. Kuala Lumpur: Institute for Medical Research
(IMR);1997.
2. Shahar S, Yusoff NM, Safii NS, et al. Atlas of food exchanges & portion
sizes (3rd edition). Kuala Lumpur: MDC Publishers; 2015.
39
Management of Diabetes in Pregnancy
Appendix 3
40
Management of Diabetes in Pregnancy
Appendix 3
41
Management of Diabetes in Pregnancy
Appendix 3
42
Management of Diabetes in Pregnancy
Appendix 3
Fat
(Each item contains 5 g of fat and 45 calories. Some of the foods
in the list, e.g. nuts and seeds also contain small amounts
of carbohydrate and protein)
Oil (all types) 1 level teaspoon (5 g)
Can be exchanged for
Butter, margarine
Mayonnaise 1 level teaspoon
Shortening, lard
Peanut butter (smooth or crunchy) 2 level teaspoons
Cream, unwhipped (heavy)
Cream cheese 1 level tbsp
Salad dressing
Cream, unwhipped (light)
Coconut, shredded
2 level tbsp
Coconut milk (santan)
Non dairy creamer, powder
Almond 6 whole
Cashew nut 6 whole
Walnut 1 whole
Peanut 20 small
Sesame seed 1 level tbsp
Watermelon seed (kuachi) with shell ¼ whole
Adapted: Malaysian Dietitians’ Association. Medical Nutrition Therapy Guidelines for
Type 2 Diabetes Mellitus. 2013.
43
Management of Diabetes in Pregnancy
Appendix 3
44
Management of Diabetes in Pregnancy
Appendix 3
SAMPLE MENU
(FOR 2000 KCAL/DAY*)
(This sample menu provides ~ 48% carbohydrate, 18% protein and
34% fat from energy)
45
Management of Diabetes in Pregnancy
Appendix 4
MEDICATION TABLE
Insulin
Types of Insulin Onset of Peak Duration Timing of
preparation Action Action of Action Administration of
(hours) Insulin
PRANDIAL
Short-acting, 30-60 min 2-4 6-10 30 min
Regular before meal
Actrapid
Humulin R
Insugen R
Insuman R
BASAL
Intermediate-acting, 1-2 hour 4-8 8-12 Pre-breakfast
NPH /pre-bed
Insulatard
Humulin N
Insugen N
Insuman N
PREMIXED INSULIN
Mixtard 30 30 min Dual 18-23 30-60 min
before meals
Humulin 30/70 30 min Dual 16-18 30-60 min
before meals
Novomix 30 10-20 min 1-4 16-20 5-15 min
before meals
Humalog mix 25/75 15 min 0.25-2.5 16-18 5-15 min
before meals
Humalog mix 50/50 15 min 0.25-2.5 16-18 5-15 min
before meals
46
Management of Diabetes in Pregnancy
47
Management of Diabetes in Pregnancy
Appendix 5
Principles of infusion:
Glucose is infused intravenously at a fixed rate. Insulin is administered
intravenously at a variable rate. CBG is checked hourly and insulin
infusion rate adjusted accordingly to maintain target CBG range.
Women with T1DM need to have some insulin in their system at all
times to avoid diabetic ketoacidosis. Those with T2DM or GDM may
or may not require insulin infusion. Insulin requirements decrease after
delivery of the placenta.
48
Management of Diabetes in Pregnancy
LIST OF ABBREVIATIONS
49
Management of Diabetes in Pregnancy
ACKNOWLEDGEMENT
DISCLOSURE STATEMENT
SOURCE OF FUNDING
50